India, May 13 -- Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, has initiated Phase 3 clinical trials inIndiaon Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April.

Glenmark is the first company inIndiato initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients inIndia. Favipiravir is a generic version of Avigan(R) of Fujifilm Toyama Chemical Co. Ltd.,Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals inIndiaare being enrolled for the study. Glenmark estimates study completion by July/August 2020.

Glenmark has successfully developed the API and the formulatio...